Provided by Tiger Trade Technology Pte. Ltd.

Scholar Rock Holding Corp

58.20
+1.703.01%
Post-market: 58.200.00000.00%19:30 EDT
Volume:1.22M
Turnover:70.56M
Market Cap:7.09B
PE:-17.32
High:58.75
Open:56.80
Low:55.90
Close:56.50
52wk High:58.75
52wk Low:27.07
Shares:121.79M
Float Shares:107.73M
Volume Ratio:1.02
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3601
EPS(LYR):-3.4845
ROE:-167.77%
ROA:-58.82%
PB:27.93
PE(LYR):-16.70

Loading ...

Canaccord Genuity Initiates Scholar Rock at Buy With $62 Price Target

MT Newswires Live
·
Apr 21

Scholar Rock initiated with a Buy at Canaccord

TIPRANKS
·
Apr 21

BRIEF-Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 18

Scholar Rock grants inducement equity awards covering 89,304 shares to new hires

Reuters
·
Apr 18

Scholar Rock to report first-quarter financial results, host conference call

Reuters
·
Apr 16

A Look At Scholar Rock (SRRK) Valuation After Apitegromab BLA Resubmission And Reduced Regulatory Risk

Simply Wall St.
·
Apr 07

Scholar Rock Holding Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 01

Scholar Rock Holding Corp : Raymond James Raises Target Price to $60 From $53

THOMSON REUTERS
·
Apr 01

Scholar Rock price target raised to $58 from $51 at BofA

TIPRANKS
·
Apr 01

BUZZ-U.S. STOCKS ON THE MOVE -Shake Shack, Perpetua, Caribou Biosciences

Reuters
·
Apr 01

Scholar Rock rises 15.5%

TIPRANKS
·
Mar 31

Wedbush Adjusts Price Target on Scholar Rock Holding to $58 From $56, Maintains Outperform Rating

MT Newswires Live
·
Mar 31

What Sent Scholar Rock Holding Stock (SRRK) Higher Today?

TIPRANKS
·
Mar 31

Scholar Rock up 12% at $48.27 after resubmitting BLA to FDA for apitegromab

TIPRANKS
·
Mar 31

BUZZ-Scholar Rock up after refiling FDA application for genetic disorder drug

Reuters
·
Mar 31

Scholar Rock Resubmits Biologics License Application for Apitegromab to US FDA

MT Newswires Live
·
Mar 31

Scholar Rock Holding Corp: Anticipates FDA Acceptance of Bla Within 30 Days and a Review Period of up to 6 Months From Date of Resubmission

THOMSON REUTERS
·
Mar 31

Scholar Rock Holding: During Meeting & FDA Site Visit, No Additional Corrective Actions Were Requested by FDA to Novo Nordisk's Remediation Plan

THOMSON REUTERS
·
Mar 31

Scholar Rock Resubmits Biologics License Application (Bla) to FDA for Apitegromab for Treatment of Children and Adults With Spinal Muscular Atrophy (Sma)

THOMSON REUTERS
·
Mar 31

Scholar Rock Holding Corp: Pdufa Action Date Expected in Late September 2026

THOMSON REUTERS
·
Mar 31